
Agenus (AGEN) Stock Forecast & Price Target
Agenus (AGEN) Analyst Ratings
Bulls say
Agenus is valued positively at $25 per share through a DCF analysis. While risks exist due to safety concerns, efficacy, and competition, the company has a differentiated pipeline with potential for value creation. This includes the potential for a patent extension, consistent and strong results in clinical trials, and a favorable safety profile in comparison to other treatments. These factors, along with the potential for achieving the necessary pCR for a positive outcome in the ROBBIN trial, support a positive outlook for the company's stock.
Bears say
Agenus is continuing to rely heavily on pre-commercial revenues, while posting an EPS of ($0.01) for 2Q26 due to operating expenses of $23.2M may prove detrimental in the long-term, as the company’s shift in strategy to the neoadjuvant setting may result in increased operating expenses and reliance on future financing. Additionally, risks to achieving the $25 PT include potential safety or efficacy issues, increased competition, changes to current programs and regulatory concerns.
This aggregate rating is based on analysts' research of Agenus and is not a guaranteed prediction by Public.com or investment advice.
Agenus (AGEN) Analyst Forecast & Price Prediction
Start investing in Agenus (AGEN)
Order type
Buy in
Order amount
Est. shares
0 shares